Published in J Neurosurg on June 01, 1995
The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther (2006) 2.10
Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer. J Neurosurg (2011) 1.87
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol (2010) 1.78
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther (2009) 1.55
Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum. Laboratory investigation. J Neurosurg (2010) 1.50
Convection-enhanced delivery of M13 bacteriophage to the brain. J Neurosurg (2012) 1.42
Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg (2008) 1.40
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol (2007) 1.39
Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. NMR Biomed (2011) 1.30
Image-guided convection-enhanced delivery of muscimol to the primate brain. J Neurosurg (2010) 1.29
AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Exp Neurol (2005) 1.29
Dilation and degradation of the brain extracellular matrix enhances penetration of infused polymer nanoparticles. Brain Res (2007) 1.25
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg (2007) 1.24
Immunotherapy of malignant brain tumors. Immunol Rev (2008) 1.20
Convection-enhanced delivery of maghemite nanoparticles: Increased efficacy and MRI monitoring. Neuro Oncol (2008) 1.14
O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging (2005) 1.14
β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res (2013) 1.12
Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics (2009) 1.08
Enhanced survival and cure of F98 glioma-bearing rats following intracerebral delivery of carboplatin in combination with photon irradiation. Clin Cancer Res (2007) 1.07
Quantitative assessment of macromolecular concentration during direct infusion into an agarose hydrogel phantom using contrast-enhanced MRI. Magn Reson Imaging (2008) 1.04
Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro Oncol (2005) 0.98
Targeted delivery of bleomycin to the brain using photo-chemical internalization of Clostridium perfringens epsilon prototoxin. J Neurooncol (2009) 0.95
Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles. Int J Nanomedicine (2011) 0.93
In vivo performance of a microelectrode neural probe with integrated drug delivery. Neurosurg Focus (2009) 0.92
Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. J Neurooncol (2009) 0.90
Site-specific opening of the blood-brain barrier. J Biophotonics (2010) 0.90
Local distribution and toxicity of prolonged hippocampal infusion of muscimol. J Neurosurg (2005) 0.90
Disruption of the blood-brain barrier following ALA-mediated photodynamic therapy. Lasers Surg Med (2008) 0.88
Highly PEGylated DNA Nanoparticles Provide Uniform and Widespread Gene Transfer in the Brain. Adv Healthc Mater (2015) 0.85
Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists omega-conotoxin GVIA and omega-conotoxin MVIIA. J Pharmacol Exp Ther (2007) 0.84
Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. Neoplasia (2003) 0.83
Tracking accuracy of T2- and diffusion-weighted magnetic resonance imaging for infusate distribution by convection-enhanced delivery. J Neurosurg (2011) 0.82
Corrective GUSB transfer to the canine mucopolysaccharidosis VII brain. Mol Ther (2013) 0.82
Effect of needle insertion speed on tissue injury, stress, and backflow distribution for convection-enhanced delivery in the rat brain. PLoS One (2014) 0.82
Anatomical differences determine distribution of adenovirus after convection-enhanced delivery to the rat brain. PLoS One (2011) 0.79
Comparison of intraprostatic ethanol diffusion using a microporous hollow fiber catheter versus a standard needle. J Urol (2012) 0.78
Convection-enhanced drug delivery for gliomas. Surg Neurol Int (2015) 0.78
Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas. Ther Deliv (2015) 0.77
Spatiotemporally photoradiation-controlled intratumoral depot for combination of brachytherapy and photodynamic therapy for solid tumor. Biomaterials (2015) 0.77
Interstitial continuous infusion therapy in a malignant glioma model in rats. Childs Nerv Syst (2009) 0.77
In vivo contrast-enhanced MR imaging of direct infusion into rat peripheral nerves. Ann Biomed Eng (2011) 0.76
Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer. Ther Deliv (2015) 0.76
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier. Curr Pharm Des (2016) 0.76
Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg (2016) 0.76
Convection-Enhanced Delivery. Neurotherapeutics (2017) 0.75
Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma. Curr Neuropharmacol (2016) 0.75
Intraprostatic ethanol diffusion: comparison of two injection methods using ex vivo human prostates. Prostate Cancer Prostatic Dis (2015) 0.75
The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model. Childs Nerv Syst (2012) 0.75
Drug-carrying microbubbles as a theranostic tool in convection-enhanced delivery for brain tumor therapy. Oncotarget (2017) 0.75
Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A (1994) 6.61
In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 5.47
Elucidating the pathophysiology of syringomyelia. J Neurosurg (1999) 4.43
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol (2001) 2.86
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology (2008) 2.80
Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med (1997) 2.76
In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res (1993) 2.74
Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest (1993) 2.42
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med (1997) 2.39
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology (2009) 2.37
Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A (2000) 2.19
Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res (1992) 2.17
Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro. Life Sci (1990) 2.04
High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol (1994) 2.01
The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome: a comparison. Ann Intern Med (1994) 2.00
Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg (1999) 1.97
Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol (1993) 1.93
Spinal arteriovenous malformations: a comparison of dural arteriovenous fistulas and intradural AVM's in 81 patients. J Neurosurg (1987) 1.92
Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med (1994) 1.78
Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol (1999) 1.77
Reversible acute and subacute myelopathy in patients with dural arteriovenous fistulas. Foix-Alajouanine syndrome reconsidered. J Neurosurg (1989) 1.75
Brief report: relief of spinal cord compression from vertebral hemangioma by intralesional injection of absolute ethanol. N Engl J Med (1994) 1.75
von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol (1997) 1.74
Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med (1994) 1.70
Multiple pituitary adenomas in Cushing's disease. J Neurosurg (2000) 1.63
Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest (1996) 1.63
Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA (1997) 1.63
Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates. J Neurosurg (1999) 1.59
Symptomatic vertebral hemangiomas: treatment by means of direct intralesional injection of ethanol. Radiology (2000) 1.58
Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology (2006) 1.57
Surgical interruption of intradural draining vein as curative treatment of spinal dural arteriovenous fistulas. J Neurosurg (1995) 1.56
Tumor devascularization by intratumoral ethanol injection during surgery. Technical note. J Neurosurg (1998) 1.55
Bilateral sampling of the internal jugular vein to distinguish between mechanisms of adrenocorticotropic hormone-dependent Cushing syndrome. Ann Intern Med (1998) 1.54
Direct convective delivery of macromolecules to the spinal cord. J Neurosurg (1998) 1.53
Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function. J Neurosurg (1997) 1.49
Extrapituitary parasellar microadenoma in Cushing's disease. J Clin Endocrinol Metab (1999) 1.49
The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies. J Neurosurg (1990) 1.48
Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. J Neurosurg (1991) 1.46
Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity. Case reports and follow-up of nine patients. Ann Intern Med (1989) 1.46
Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther (1993) 1.44
Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci (1986) 1.39
The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome. N Engl J Med (1984) 1.36
Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J Neuropathol Exp Neurol (1999) 1.35
Direct convective delivery of macromolecules to peripheral nerves. J Neurosurg (1998) 1.35
Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther (1997) 1.33
Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg (1997) 1.32
Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res (1997) 1.31
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol Ther (2001) 1.31
Neurosurgical implications of Carney complex. J Neurosurg (2000) 1.30
Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther (2012) 1.29
Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg (1989) 1.27
Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. Neuroreport (2001) 1.26
Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant (2000) 1.21
Management of the ectopic ACTH syndrome due to thoracic carcinoids. Ann Thorac Surg (1990) 1.20
6-[18F]fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates. Brain Res (1997) 1.15
Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab (2001) 1.14
Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab (1999) 1.14
Successful treatment of a group of spinal cord arteriovenous malformations by interruption of dural fistula. J Neurosurg (1983) 1.13
Resection of suprasellar tumors by using a modified transsphenoidal approach. Report of four cases. J Neurosurg (2000) 1.13
Treatment of cranial dural arteriovenous fistulae by interruption of leptomeningeal venous drainage. J Neurosurg (1994) 1.12
Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone. J Neurosurg (1987) 1.12
A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab (1994) 1.12
Evolution of VHL tumourigenesis in nerve root tissue. J Pathol (2006) 1.11
In vitro generation and transplantation of precursor-derived human dopamine neurons. J Neurosci Res (2001) 1.09
Early repeat surgery for persistent Cushing's disease. J Neurosurg (1994) 1.09
Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg (1996) 1.06
Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1. Cancer Res (1991) 1.06
Temporal changes in perivascular concentrations of oxyhemoglobin, deoxyhemoglobin, and methemoglobin after subarachnoid hemorrhage. J Neurosurg (1998) 1.06
Spinal cord swelling preceding syrinx development. Case report. J Neurosurg (2000) 1.06
Usefulness of inferior petrosal sinus venous endocrine markers in Cushing's disease. J Neurosurg (1988) 1.06
Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol Endocrinol (2001) 1.05
Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab (2000) 1.04
A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab (1993) 1.04
Neurologic complications of petrosal sinus sampling. Radiology (1992) 1.04
Role of ferrous iron chelator 2,2'-dipyridyl in preventing delayed vasospasm in a primate model of subarachnoid hemorrhage. J Neurosurg (1998) 1.04
Gene transfer technologies for malignant gliomas. Curr Opin Oncol (1999) 1.03
Recanalization of spinal arteriovenous malformations following embolization. J Neurosurg (1989) 1.02
Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. N Engl J Med (1985) 1.02
Cytosolic calcium changes in endothelial cells induced by a protein product of human gliomas containing vascular permeability factor activity. J Neurosurg (1989) 1.02
The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg (1994) 1.01
Repeat transsphenoidal surgery for Cushing's disease. J Neurosurg (1989) 1.01
Microvascular anatomy of dural arteriovenous abnormalities of the spine: a microangiographic study. J Neurosurg (1996) 1.00
Quantitative examination of tissue concentration profiles associated with microdialysis. J Neurochem (1992) 1.00
Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas. Cancer Res (1992) 1.00
The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome. Ann Intern Med (1986) 0.99
Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain. Gene Ther (2013) 0.99
Source and cause of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg (1997) 0.99